Program

NSGO-CTU Biannual Investigator Meeting
19 April 2018
16:00-17:30

Moderators: Mansoor Raza Mirza and Johanna Mäenpää

Current Status & Future Goals of NSGO-CTU (10 min)  Mansoor Raza Mirza

New Trials in Pipeline (40 min)  Mansoor Raza Mirza

Ovarian Cancer first-line

TRUST, AGO-OVAR OP.7/AGO-OVAR 19: A multicenter prospective randomized study of primary radical vs. interval debulking surgery for adv. ovarian ca.

FIRST, ENGOT-ov44/GINECO: First-line ovarian cancer treatment with Niraparib plus TSR-042, A RANDOMIZED PHASE 3 COMPARING PLATINUM and TSR-042 (PD-L1 inhibitor) FOLLOWED BY NIRAPARIB and TSR-042 MAINTENANCE Therapy versus ADAPTATIVE STandard Platinum-Based treatment in Patients with Stage III or IV Cancer of the Ovary, Fallopian Tube or peritoneum

DUO-0: A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab (MEDI4736) in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-0).

ATHENA, ENGOT-OV45/NCRI: A Multicenter, Randomised, Double-Blind, Placebo-Controlled Phase 3 study in Ovarian Cancer Patients evaluating Rucaparib and Nivolumab as Maintenance Treatment following response to Front-line Platinum-based Chemotherapy.

Ovarian Cancer recurrent disease

AVANOVA Part 3-ENGOT ov42

ENGOT-OV34 / AGO2.29: Atezolizumab in combination with Bevacizumab and Chemotherapy versus Chemo-Bevacizumab standard in recurrent ovarian cancer – a randomized Phase III trial

Endometrial Cancer

ENGOT-EN6/TSR042 / NSGO
Cervical Cancer
Senticol III: International Validation study of sentinel node biopsy in early cervical cancer.


ENGOT-Cx7 / NSGO MaRuC: A randomized double-blind placebo-controlled phase II trial of Rucaparib maintenance therapy for patients with locally advanced cervical cancer

ADXS 601-ENGOT Cx5: A Parallel-Arm, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of ADXS-601 in Combination with Nivolumab Compared with Investigator’s Choice of Single-Agent Chemotherapy in Patients with Recurrent or Metastatic Cervical Cancer who have Failed or were Ineligible to Receive First-Line Chemotherapy with or without Bevacizumab.

ENGOT-Cx6 / TISOTUMAB: A Single arm, Multicenter, Phase 2b Trial Investigating the Efficacy of Tisotumab Vedotin (HuMax® -TF-ADC) Therapy in Previously treated Patients with Recurrent or Metastatic Cervical Cancer.

ENGOT-Cx8: A Phase 2 Open-Label Trial of Tisotumab Vedotin (HuMax® -TF-ADC) alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer.

BEAT: GINECO proposal; A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent or Recurrent Carcinoma of the Cervix- BEAT cc

Vulvar Cancer
GROINS V: Groninge International Study On Sentinel Nodes In Vulvar Cancer (GROINSS-V) III a Prospective Phase II Treatment Trial

Status on Ongoing Trials (40 min) Johanna Mäenpää

Ovarian Cancer:
ENGOT-OV30 / PRIMA: A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

IMagyn050: A phase III study of Atezolizumab in the treatment of front-line ovarian cancer

EWOC-1: Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage III-IV advanced ovarian cancer

NICCC - A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium


ENGOT-OV16 / NOVA: A phase 3 randomized double-blind trial of maintenance with Niraparib versus placebo in patients with platinum sensitive ovarian cancer
ARIEL4: A Phase 3 Multicenter, Open-Label, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Endometrial Cancer:
EN1 – FANDANGO – A Randomized Phase II Trial of First-line Combination Chemotherapy With Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial Cancer

EN2 – A phase III Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer

EN3 – PALEO – A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus Placebo in combination with Letrozole for patients with Estrogen Receptor Positive advanced or recurrent Endometrial cancer